Skip to content
10-Q

Quarterly Report

Goldenwell Biotech, Inc. GWLL

0001477932-24-003169

← back to feed
Filed
May 20, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 15, 2024 99M sh
Total Liabilities Q1 2024 · Mar 31, 2024 $145.22K
Total Liabilities Q1 2024 · Dec 31, 2023 $143.33K
Total Assets Q1 2024 · Mar 31, 2024 $198.97K
Total Assets Q1 2024 · Dec 31, 2023 $228.06K
Revenue Q1 2024 · Mar 31, 2024 $158
Revenue Q1 2024 · Mar 31, 2023 $1.42K
Net Income Q1 2024 · Dec 31, 2023 −$20.8K
Net Income Q1 2024 · Sep 30, 2023 −$35.41K
Net Income Q1 2024 · Jun 30, 2023 −$27.08K
Net Income Q1 2024 · Mar 31, 2023 −$33.61K
Stockholders Equity Q1 2024 · Sep 30, 2023 $105.52K
Stockholders Equity Q1 2024 · Jun 30, 2023 $140.93K
Stockholders Equity Q1 2024 · Mar 31, 2023 $168.01K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$31.92K
Operating Income Q1 2024 · Mar 31, 2023 −$33.61K
Gross Profit Q1 2024 · Mar 31, 2023 $711
Cost Of Revenue Q1 2024 · Mar 31, 2023 $711